NO. BPPI/DRUG-040/2016

Date-22/06/2016

AMENDMENT NO. 1

Subject:- Tender No. BPPI/DRUG-040/2016 Dated 09.06.2016 for supply of Drugs and Medicines to bureau of Pharma Public Sector Undertakings of India (BPPI) for the year 2016-18.

Reference:- Pre-Bid meeting held on 17.06.2016 at 11:00AM in the premises of BPPI

In view of discussion held in pre-bid meeting on 17.06.2016, the following amendment in subject tender document is hereby authorized:-

I. Clause 4.1(g) under para 4. TECHNICAL BID- COVER A

FOR:-

(g) MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY UNDER generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years (Certificate should be uploaded with list of items) for minimum 3 batches of medicine. In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be uploaded. MSC issued under brand name or under generic name (by the state licensing authority) will also be accepted but supplies will be accepted only in International Non-proprietary Name (INN) / generic name. However, for those newly launched drugs and medicines whose first product permission to manufacture and sale has been issued within 2 years by the respective country’s / state drug authority, MARKET STANDING CERTIFICATE (MSC) issued by the respective country’s /STATE LICENSING AUTHORITY under generic or brand name as a Manufacturer for less than 2 years shall be acceptable to BPPI.

READ:-

(g) MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY UNDER generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years (Certificate should be uploaded with list of items) for minimum 3 batches of medicine. For minimum 3 batches of medicines, the certificate by their CA (CHARTERED ACCOUNTANT) shall also be acceptable if licencing authority is unable to provide the certificate. In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be uploaded. MSC issued under brand name or under generic name (by the state licensing authority) will also be accepted but supplies will be accepted only in International Non-proprietary Name (INN) / generic name. However, for those newly launched drugs and medicines whose first product permission to manufacture and sale has been issued within 2 years by the respective country’s / state drug...
authority, MARKET STANDING CERTIFICATE (MSC) issued by the respective country’s /STATE LICENSING AUTHORITY under generic or brand name as a Manufacturer for less than 2 years shall be acceptable to BPPI.

II. Add the following under Clause 9.1 of tender document:-

In case of lower total tentative quantity, the distribution to L2 & L3 may be considered on case to case basis after finalization of the whole process.

III. Add the following under Clause 12.4 (a) and (b) of tender document:-

Delivery period for imported drugs shall be 90 days for each supply.

IV. The Approximate Tender Quantity indicated under column 7 of Annexure XII and respective column of BOQ is in terms of number in unit size as per column 4 of Annexure XII & BOQ.

V. Drug code 1023 & 936

(i) The description, unit size, pack size and Packing per carton specification in Annexure XII( Modified on 17/06/2016) is amended as under:-

For:-

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Drug Code</th>
<th>Generic Name of Medicines</th>
<th>Unit Size</th>
<th>Pack size</th>
<th>Packing per carton specification</th>
</tr>
</thead>
<tbody>
<tr>
<td>83</td>
<td>1023</td>
<td>Progesterone Inj. I.P 100mg</td>
<td>1's</td>
<td>1's x 10</td>
<td>(1’s x 10 x 10) x 10</td>
</tr>
<tr>
<td>170</td>
<td>936</td>
<td>Leuprolide Acetate Injections 3.75mg</td>
<td>1’s</td>
<td>1’s x 10</td>
<td>(1’s x 10 x 10) x 10</td>
</tr>
</tbody>
</table>

Read :-

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Drug Code</th>
<th>Generic Name of Medicines</th>
<th>Unit Size</th>
<th>Pack size</th>
<th>Packing per carton specification</th>
</tr>
</thead>
<tbody>
<tr>
<td>83</td>
<td>1023</td>
<td>Progesterone Inj. I.P 100mg/ml</td>
<td>2ml amp.</td>
<td>2ml x 10</td>
<td>(2ml x 10 x 10) x 10</td>
</tr>
<tr>
<td>170</td>
<td>936</td>
<td>Leuprolide Acetate Injections 3.75mg</td>
<td>2ml amp.</td>
<td>2ml x 10</td>
<td>(2ml x 10 x 10) x 10</td>
</tr>
</tbody>
</table>

Accordingly Description, Unit Size for Drug code 1023 and 936 in BOQ may be read as above.

VI. Drug code 749 is hereby amended as 585 in Annexure XII and also read in BOQ.

All other contents of the tender document are unaltered.

(Mahadev Agarwal)
Manager(Procurement),BPPI